Key Highlights

  • An all-share Merger with a Nasdaq-listed company would give access to a US listing, with the target holding $19.4m and one employee.
  • A $39.1m private Placement at 9p per ordinary share was joined by a UK placing upsized to £13.0m and a £2.7m retail offer.
  • Pro forma net cash was put at £59.2m, with the runway extended into 2029.
  • Regulatory clearance for the Phase 3 registrational trial came in the UK in August, following US clearance in January.

Scancell Holdings Plc (LSE:SCLP), the UK cancer immunotherapy developer, has spent the summer rewriting its own story. On 23 July 2026 it unveiled an all-share merger with Nasdaq-listed Neuphoria Therapeutics, a financing package of up to $89m and a plan to list American Depositary Shares on Nasdaq as "SCLT" while keeping its London quotation. On 19 August the UK's MHRA authorised the Phase 3 registrational trial of its lead melanoma vaccine, iSCIB1+, following FDA clearance in January and Fast Track Designation in April.

For a Business that reported just £8.6m of cash at 31 October 2025 and a runway only into the second half of 2026, the change is substantial. The question now is whether Scancell can execute a 550-patient global trial, close a complex cross-border transaction and deliver further SCOPE data within roughly twelve months.

Merger, Nasdaq listing and $89m financing announced 23 July 2026

The centrepiece is the Acquisition of Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a neuropsychiatry company whose Phase 3 AFFIRM-1 trial in social anxiety disorder missed its endpoints in October 2025. Neuphoria brings little beyond its Nasdaq listing and cash: at 31 March 2026 it held $19.4m, no material Assets and one employee. Its stockholders will receive 37.77199 Scancell ADSs per share, roughly 204.1 million consideration shares, or about 13.7% of the enlarged group after the financing.

Scancell raised money on three fronts. A $39.1m (c.£29.2m) private placement at $0.1205 per ADS, equivalent to 9p per ordinary share, was led by existing 28.6% holder Redmile, which took non-voting shares, and by Vulpes Investment Management, which is lifting its stake to 15.7%. Chief executive Dr Phil L'Huillier also subscribed. A UK placing at 9p was upsized from £9.0m to £13.0m after being "very significantly oversubscribed", and a retail offer added £2.7m. BlackRock has provided a non-binding term sheet for up to $25m of secured Debt in four tranches through December 2027, with a $7m first Tranche available before completion.

A correction on 24 July put pro forma net cash at £59.2m. The company says the package should fund the Phase 3 programme and extend its cash runway into 2029. Dr L'Huillier said the transaction "will establish Scancell on Nasdaq and enable access to US investors and the broader US life sciences sector." Completion is targeted for late Q4 2026, with an end date of 28 February 2027. Conditions include Shareholder approvals on both sides, Nasdaq approval, a minimum $75m of financing and a 10:1 share consolidation.

What Scancell does

Scancell develops cancer immunotherapies from three platforms. ImmunoBody is a DNA Vaccine technology whose lead product, iSCIB1+, trains the immune system to attack melanoma cells and is tested alongside the checkpoint inhibitors nivolumab and ipilimumab. Moditope produces off-the-shelf citrullinated peptide vaccines, with Modi-1 in the Phase 2 ModiFY trial in head and neck and renal cancers. The GlyMab antibody platform, housed since June 2025 in Subsidiary GlyMab Therapeutics, targets glycan structures on tumour cells; its lead antibody, SC134, is aimed at small cell lung cancer.

The company has no product sales. Revenue to date has come from licensing, notably two agreements with Genmab A/S covering GlyMab antibodies, with potential milestones of up to $630m. Otherwise Scancell funds itself through share issues, convertible Loan notes, UK R&D tax credits and, prospectively, partnering of iSCIB1+.

Financial performance: narrower first-half loss, tight cash before the raise

Scancell's financial year runs to 30 April. For the year ended 30 April 2025, revenue was £4.7m (FY24: nil), reflecting Genmab upfront payments. Development expenses rose to £14.7m from £12.9m, administrative costs fell to £4.8m from £5.4m, and the operating loss narrowed to £15.0m from £18.3m. Loss for the year was £12.3m, against £5.9m in FY24. Cash at 30 April 2025 was £16.9m, while convertible loan notes and associated derivative liabilities totalled £23.2m.

In the six months to 31 October 2025 there was no revenue. R&D spending fell to £6.1m from £8.0m as the SCOPE Phase 2 study concluded, and the operating loss reduced to £8.9m from £10.5m. Loss before tax was £6.8m (H1 FY25: £13.8m), with basic loss per share of 0.55p (1.35p). Cash had fallen to £8.6m and the Balance Sheet showed net liabilities of £8.4m, including £15.9m of amortised convertible notes. A £3.0m R&D tax Credit arrived in December 2025. FY26 full-year results have not yet been published.

What could move the shares next

The nearest milestone is the start of the Phase 3 trial, expected by the end of 2026 across roughly 90 sites in the US, EU, UK, Canada and Australia. Its adaptive, placebo-controlled design uses progression-free survival to support accelerated approval, with an initial readout targeted for the second half of 2028. Scancell also expects further PFS and overall survival data from the SCOPE study within twelve months; the July announcement cited 77% PFS at 22 months and 87.4% overall survival at 18 months.

Corporate catalysts matter as much. The Form F-4 must become effective, both shareholder bases must vote and Nasdaq must approve the listing before the deal closes. Partnering discussions for iSCIB1+ are ongoing, Modi-1 readouts from ModiFY were guided for the first half of 2026, Genmab milestones are anticipated, and SC134 has, in the company's words, generated strong commercial interest.

Risks investors should watch

Execution risk is high. The merger could Fail to close if conditions are not met by the end date, leaving Scancell with the UK placing proceeds, which the board said were intended to extend the runway only into Q3 2027. Even if it completes, the BlackRock Facility is non-binding and adds secured, interest-bearing debt with convertible and Warrant features on top of £18.2m of convertible notes maturing in the second half of 2027.

Dilution is a live issue: about 174 million new shares were issued in July, a further 324 million underpin the private placement, and Neuphoria holders will receive 204 million more. Ownership is concentrated, with Redmile at roughly 27% post-conversion and Vulpes at 15.7%. A Phase 3 melanoma trial in combination with established checkpoint inhibitors is expensive and could still fail, and there is no product revenue to cushion any setback. Finance is led by an interim CFO, David Schilansky, following Sath Nirmalananthan's departure in April 2026.

Outlook

Scancell (LSE:SCLP) enters the autumn with a credible route to a registrational trial, more money than it has held in years and an incoming US shareholder base. It also carries a heavier share count, a pending 10:1 consolidation, an unsigned debt facility and a transaction timetable running to February 2027. Investors should watch for the FY26 results, the Form F-4 and shareholder circulars, confirmation of the first Phase 3 patient, updated SCOPE survival data and any partnering news for iSCIB1+ or SC134. Whether the London-listed story does surprise the market depends on the company keeping all those threads moving together.